TP53 and myelodysplastic syndrome: TP53 mutations are generally less frequent in de novo AML, occurring in about 10% of cases but they are more common in therapy-related AML (t-AML) and secondary AML (s-AML) that arises from a prior myelodysplastic syndrome (MDS).